Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes

Retrovirology

Volumn 6, Issue , 2009, Pages

  Bar Magen, Tamara ^a   Sloan, Richard D ^a   Faltenbacher, Verena H ^a   Donahue, Daniel A ^a,b   Kuhl, Björn D ^a,b   Oliveira, Maureen ^a   Xu, Hongtao ^a   Wainberg, Mark A ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ELVITEGRAVIR; HIV 1 INTEGRASE SUBTYPE B PROTEIN; HIV 1 INTEGRASE SUBTYPE C PROTEIN; INTEGRASE; INTEGRASE INHIBITOR; MK 2048; RALTEGRAVIR; RECOMBINANT ENZYME; UNCLASSIFIED DRUG; 2 PYRROLIDONE DERIVATIVE; P31 INTEGRASE PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; QUINOLONE DERIVATIVE; VIRUS DNA;

ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME CHEMISTRY; ENZYME INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN PROCESSING; PROTEIN TRANSPORT; CLASSIFICATION; COMPARATIVE STUDY; ENZYMOLOGY; GENETICS; GENOTYPE; IC 50; METABOLISM;

HUMAN IMMUNODEFICIENCY VIRUS 1;

DNA, VIRAL; GENOTYPE; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; INHIBITORY CONCENTRATION 50; PYRROLIDINONES; QUINOLONES;

EID: 71049125354     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-6-103     Document Type: Article

References (34)

1. Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, Gonzalez CJ, Chen J, Harvey CM, Isaacs RD. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007, 369:1261-1269. 10.1016/S0140-6736(07)60597-2, 17434401.
2. Shimura K, Kodama E, Sakagami Y, Matsuzaki Y, Watanabe W, Yamataka K, Watanabe Y, Ohata Y, Doi S, Sato M, Kano M, Ikeda S, Matsuoka M. Broad Antiretroviral Activity and Resistance Profile of the Novel Human Immunodeficiency Virus Integrase Inhibitor Elvitegravir (JTK-303/GS-9137). J Virol 2008, 82:764-774. 2224569, 17977962, 10.1128/JVI.01534-07.
3. Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Teppler H, Nguyen BY, . BENCHMRK Study Teams Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection. N Engl J Med 2008, 359:355-365. 10.1056/NEJMoa0708978, 18650513.
4. Briz V, Garrido C, Poveda E, Morello J, Barreiro P, de Mendoza C, Soriano V. Raltegravir and etravirine are active against HIV type 1 group O. AIDS Res Hum Retroviruses 2009, 25:225-227. 10.1089/aid.2008.0222, 19239363.
5. Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006, 20:W13-23. 10.1097/01.aids.0000247564.73009.bc, 17053344.
6. Sherman PA, Fyfe JA. Human immunodeficiency virus integration protein expressed in Escherichia coli possesses selective DNA cleaving activity. Proceedings of the National Academy of Sciences of the United States of America 1990, 87:5119-5123. 54273, 2164223, 10.1073/pnas.87.13.5119.
7. Bushman FD, Fujiwara T, Craigie R. Retroviral DNA integration directed by HIV integration protein in vitro. Science 1990, 249:1555-1558. 10.1126/science.2171144, 2171144.
8. Engelman A, Mizuuchi K, Craigie R. HIV-1 DNA integration: mechanism of viral DNA cleavage and DNA strand transfer. Cell 1991, 67:1211-1221. 10.1016/0092-8674(91)90297-C, 1760846.
9. Delelis O, Carayon K, Saib A, Deprez E, Mouscadet JF. Integrase and integration: biochemical activities of HIV-1 integrase. Retrovirology 2008, 5:114. 2615046, 19091057, 10.1186/1742-4690-5-114.
10. Chow SA, Vincent KA, Ellison V, Brown PO. Reversal of integration and DNA splicing mediated by integrase of human immunodeficiency virus. Science 1992, 255:723-726. 10.1126/science.1738845, 1738845.
11. Myers RE, Pillay D. Analysis of Natural Sequence Variation and Covariation in Human Immunodeficiency Virus Type 1 Integrase. J Virol 2008, 82:9228-9235. 2546890, 18596095, 10.1128/JVI.01535-07.
12. Miller M, Danovich R, Witmer M, Nguyen B-Y, Teppler H, Zhao J, Barnard R, Hazuda D, . for the HIV-1 Integrase Inhibitor Devt Teams, Protocol 004 Team, and BENCHMRK-1 and -2 Teams Emerging Patterns of Resistance to Integrase Inhibitors. 16th Conference on Retroviruses and Opportunistic Infections. Montreal 2009,
13. Malet I, Soulie C, Tchertanov L, Derache A, Amellal B, Traore O, Simon A, Katlama C, Mouscadet JF, Calvez V, Marcelin AG. Structural effects of amino acid variations between B and CRF02-AG HIV-1 integrases. J Med Virol 2008, 80:754-761. 10.1002/jmv.21169, 18360887.
14. Bushman FD, Engelman A, Palmer I, Wingfield P, Craigie R. Domains of the integrase protein of human immunodeficiency virus type 1 responsible for polynucleotidyl transfer and zinc binding. Proceedings of the National Academy of Sciences of the United States of America 1993, 90:3428-3432. 46313, 8386373, 10.1073/pnas.90.8.3428.
15. Jenkins TM, Engelman A, Ghirlando R, Craigie R. A Soluble Active Mutant of HIV-1 Integrase. J Biol Chem 1996, 271:7712-7718. 10.1074/jbc.271.13.7712, 8631811.
16. Bischerour J, Leh H, Deprez E, Brochon J-C, Mouscadet J-F. Disulfide-Linked Integrase Oligomers Involving C280 Residues Are Formed In Vitro and In Vivo but Are Not Essential for Human Immunodeficiency Virus Replication. J Virol 2003, 77:135-141. 140589, 12477818, 10.1128/JVI.77.1.135-141.2003.
17. Bushman FD, Craigie R. Activities of human immunodeficiency virus (HIV) integration protein in vitro: specific cleavage and integration of HIV DNA. Proceedings of the National Academy of Sciences of the United States of America 1991, 88:1339-1343. 51013, 1847518, 10.1073/pnas.88.4.1339.
18. Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, Espeseth A, Gabryelski L, Schleif W, Blau C, Miller MD. Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells. Science 2000, 287:646-650. 10.1126/science.287.5453.646, 10649997.
19. Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/Aids. Nat Rev Drug Discov 2005, 4:236-248. 10.1038/nrd1660, 15729361.
20. Vacca JWJ, Fisher T, Embrey M, Hazuda D, Miller M, Felock P, Witmer M, Gabryelski L, Lyle T. Discovery of MK-2048 - subtle changes confer unique resistance properties to a series of tricyclic hydroxypyrrole integrase strand transfer inhibitors. 4th IAS Conference. Sydney, Australia 2007,
21. Wai JTF, Embrey M, Egbertson M, Vacca J, Hazuda D, Miller M, Witmer M, Gabryelski L, Lyle T. Next generation of inhibitors of HIV-1 integrase strand transfer inhibitor: structural diversity and resistance profiles. Conf Retrovir Opportunistic Infect 2007. Los Angeles, California 2007,
22. Marinello J, Marchand C, Mott BT, Bain A, Thomas CJ, Pommier Y. Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. Biochemistry 2008, 47:9345-9354. 2660605, 18702518, 10.1021/bi800791q.
23. Malet I, Delelis O, Valantin M-A, Montes B, Soulie C, Wirden M, Tchertanov L, Peytavin G, Reynes J, Mouscadet J-F, Katlama C, Calvez V, Marcelin AG. Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro. Antimicrob Agents Chemother 2008, 52:1351-1358. 2292515, 18227187, 10.1128/AAC.01228-07.
24. Grobler JA, Stillmock K, Hu B, Witmer M, Felock P, Espeseth AS, Wolfe A, Egbertson M, Bourgeois M, Melamed J, Wai JS, Young S, Vacca J, Hazuda DJ. Diketo acid inhibitor mechanism and HIV-1 integrase: Implications for metal binding in the active site of phosphotransferase enzymes. PNAS 2002, 99:6661-6666. 124459, 11997448, 10.1073/pnas.092056199.
25. Martinez-Cajas JL, Pai NP, Klein MB, Wainberg MA. Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008). J Int AIDS Soc 2009, 12:11. 2713201, 19566959, 10.1186/1758-2652-12-11.
26. Hazuda DJ, Anthony NJ, Gomez RP, Jolly SM, Wai JS, Zhuang L, Fisher TE, Embrey M, Guare JP, Egbertson MS, Vacca JP, Huff JR, Felock PJ, Witmer MV, Stillmock KA, Danovich R, Grobler J, Miller MD, Espeseth AS, Jin L, Chen IW, Lin JH, Kassahun K, Ellis JD, Wong BK, Xu W, Pearson PG, Schleif WA, Cortese R, Emini E, Summa V, Holloway MK, Young SD. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. PNAS 2004, 101:11233-11238. 509174, 15277684, 10.1073/pnas.0402357101.
27. Savarino A. In-Silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate. Retrovirology 2007, 4:21. 1847836, 17374162, 10.1186/1742-4690-4-21.
28. Loizidou EZ, Kousiappa I, Zeinalipour-Yazdi CD, Vijver DAMC, Kostrikis LG. Implications of HIV-1 M Group Polymorphisms on Integrase Inhibitor Efficacy and Resistance: Genetic and Structural in Silico Analyses. Biochemistry 2009, 48:4-6. 10.1021/bi8019349, 19090674.
29. Xu HT, Martinez-Cajas JL, Ntemgwa ML, Coutsinos D, Frankel FA, Brenner BG, Wainberg MA. Effects of the K65R and K65R/M184V reverse transcriptase mutations in subtype C HIV on enzyme function and drug resistance. Retrovirology 2009, 6:14. 2644664, 19210791.
30. Debyser Z, Cherepanov P, Pluymers W, Clercq E. Assays for the Evaluation of HIV-1 Integrase Inhibitors. 2001, 160:139-155.
31. Hazuda DJ, Hastings JC, Wolfe AL, Emini EA. A novel assay for the DNA strand-transfer reaction of HIV-1 integrase. Nucleic Acids Res 1994, 22:1121-1122. 307941, 8152918, 10.1093/nar/22.6.1121.
32. Debyser Z, Cherepanov P, Pluymers W, De Clercq E. Assays for the evaluation of HIV-1 integrase inhibitors. Methods Mol Biol 2001, 160:139-155.
33. Brenner BG, Oliveira M, Doualla-Bell F, Moisi DD, Ntemgwa M, Frankel F, Essex M, Wainberg MA. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS 2006, 20:F9-13. 10.1097/01.aids.0000232228.88511.0b, 16816549.
34. Cotte L, Trabaud MA, Tardy JC, Brochier C, Gilibert RP, Miailhes P, Trepo C, Andre P. Prediction of the virological response to etravirine in clinical practice: Comparison of three genotype algorithms. J Med Virol 2009, 81:672-677. 10.1002/jmv.21461, 19235860.